Perspective Therapeutics (NYSE:CATX) Shares Gap Up Following Insider Buying Activity

Perspective Therapeutics, Inc. (NYSE:CATX) gapped up before the market opened on Friday after an insider bought additional shares in the company. The stock had previously closed at $1.16, but opened at $1.29. Perspective Therapeutics shares last traded at $1.21, with a volume of 735,931 shares traded.

Specifically, CEO Johan M. Spoor bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The shares were acquired at an average cost of $1.17 per share, for a total transaction of $117,000.00. Following the acquisition, the chief executive officer now directly owns 137,572 shares of the company’s stock, valued at approximately $160,959.24. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Lori A. Woods bought 34,246 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average cost of $1.46 per share, for a total transaction of $49,999.16. Following the acquisition, the director now directly owns 1,553,984 shares of the company’s stock, valued at approximately $2,268,816.64. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Johan M. Spoor bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The stock was bought at an average price of $1.17 per share, for a total transaction of $117,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 137,572 shares in the company, valued at $160,959.24. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 244,283 shares of company stock valued at $317,849. Corporate insiders own 3.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CATX. Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. Oppenheimer reissued an “outperform” rating and set a $1.50 price objective (up previously from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st. B. Riley lifted their price objective on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research report on Tuesday, April 9th. Cantor Fitzgerald began coverage on Perspective Therapeutics in a research report on Thursday, May 9th. They set an “overweight” rating for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price objective on shares of Perspective Therapeutics in a research report on Friday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $1.90.

Perspective Therapeutics Trading Down 7.8 %

The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics’s stock is set to reverse split before the market opens on Monday, June 17th. The 1-10 reverse split was announced on Monday, June 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, June 17th.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Perspective Therapeutics had a negative return on equity of 46.38% and a negative net margin of 302.70%. The company had revenue of $0.33 million during the quarter. As a group, research analysts predict that Perspective Therapeutics, Inc. will post -0.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. HighTower Advisors LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at $314,000. Taylor & Morgan Wealth Management LLC increased its stake in shares of Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after buying an additional 50,000 shares during the period. Simplicity Wealth LLC acquired a new stake in shares of Perspective Therapeutics in the 1st quarter valued at $40,000. ZWJ Investment Counsel Inc. acquired a new stake in shares of Perspective Therapeutics in the 1st quarter valued at $26,000. Finally, RIA Advisory Group LLC increased its stake in shares of Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after buying an additional 99,293 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.